Allakos Inc (ALLK)

Currency in USD
0.329
0.000(0.00%)
Closed·
Showing Allakos historical data. For real-time data please try another search
Fair Value
Day's Range
0.3280.330
52 wk Range
0.2161.555
Key Statistics
Prev. Close
0.329
Open
0.328
Day's Range
0.328-0.33
52 wk Range
0.216-1.555
Volume
725.84K
Average Volume (3m)
1.18M
1-Year Change
-64.05%
Book Value / Share
0.62
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALLK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Allakos Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Allakos Inc Company Profile

Allakos Inc. operates as a clinical stage biotechnology company that develops monoclonal antibodies that target immunomodulatory receptors present on the surface of immune effector cells involved in allergy, inflammatory, and proliferative diseases. The company was incorporated in 2012 and is based in San Carlos, California. As of May 15, 2025, Allakos Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Allakos Inc SWOT Analysis


AK006 Breakthrough
Explore Allakos's flagship anti-Siglec-6 monoclonal antibody, AK006, showing promising results in Phase 1 trials for chronic spontaneous urticaria treatment
Financial Resilience
Delve into Allakos's financial strategy, with a cash runway extending into mid-2026, supporting ongoing clinical development amid market volatility
Market Dynamics
Analyst targets range from $1.40 to $7.00, reflecting diverse views on Allakos's potential in the competitive CSU treatment landscape
Strategic Horizons
Learn about Allakos's potential for expansion beyond CSU, leveraging AK006's mechanism to address multiple mast cell-mediated disorders
Read full SWOT analysis

Compare ALLK to Peers and Sector

Metrics to compare
ALLK
Peers
Sector
Relationship
P/E Ratio
−0.4x−0.6x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
0.5x2.3x2.6x
Price / LTM Sales
-4.5x3.2x
Upside (Analyst Target)
6.4%170.0%41.2%
Fair Value Upside
Unlock8.9%6.2%Unlock

Earnings

Latest Release
May 19, 2025
EPS / Forecast
-0.29 / -0.2886
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ALLK Income Statement

People Also Watch

1.930
KOPN
-5.85%
156.33
CAH
-0.52%
1.690
LDI
-5.06%
13.98
PCG
-0.71%
172.60
STZ
-1.66%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.